ArticleJournal of biomedical science2019
Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine.
Article in Journal of biomedical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 1 synthesis or guideline pooled it, 387 citations in OpenAlex.
- Agronomic biofortification of food crops: An emerging opportunity for global food and nutritional security.Frontiers in plant science · 2022Pooled it
- Prognostic Value of Clinical and Laboratory Markers in Hospitalized Influenza-Positive Patients: A Retrospective Cohort Study With ROC-Based Risk Stratification.Health science reports · 2026Article
- ROS-mitochondria-NLRP3/STING axis mediates the enhanced anti-coronavirus activity of ZIF8 nanoparticles.Journal of nanobiotechnology · 2026Article
- Nanomedicine in maternal viral infections: advancing prenatal therapies for fetal protection.Discover nano · 2026Review
- Bio-Derived Cellulose Nanofibers for the Development Under Environmentally Assessed Conditions of Cellulose/ZnO Nanohybrids with Enhanced Biocompatibility and Antimicrobial Properties.Materials (Basel, Switzerland) · 2026Article
- Comparison of Peganum harmala L. leaves extract nanoformulations against herpes simplex virus type 1 guided by network pharmacology analysis.Scientific reports · 2025Article
- Preparation and Antiviral Activity of LaACS applied materials & interfaces · 2025Article
- Bactericidal, Virucidal, and Biocompatible Properties of 3D Printed Materials Enhanced with Copper and Zinc Nanoparticles.Global challenges (Hoboken, NJ) · 2025Article
- Revolutionizing Nanovaccines: A New Era of Immunization.Vaccines · 2025Review
- The Influence of the AgNPs Ligand on the Antiviral Activity Against HSV-2.International journal of nanomedicine · 2025Article
- Potential mechanisms of zinc sulfate in inhibiting porcine reproductive and respiratory syndrome virus replication: attenuation of oxidative stress, inflammatory response, and apoptosis.Frontiers in veterinary science · 2025Article
- Optimisation, Synthesis, and Characterisation of ZnO Nanoparticles UsingInternational journal of molecular sciences · 2024Article
- Antiviral and Cytoprotective Effect of Zinc (Yasad Bhasma) Based Nanoformulations Against Bovine Coronavirus.Indian journal of microbiology · 2024Article
- Lectins as the prominent potential to deliver bioactive metal nanoparticles by recognizing cell surface glycans.Heliyon · 2024Review
- Nanoparticle‑based antiviral strategies to combat the influenza virus (Review).Biomedical reports · 2024Review
- Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems.Pharmaceutics · 2024Review
- Article
- Antimicrobial Feature of Nanoparticles in the Antibiotic Resistance Era: From Mechanism to Application.Advanced biomedical research · 2024Review
- Recent Updates on Multifunctional Nanomaterials as Antipathogens in Humans and Livestock: Classification, Application, Mode of Action, and Challenges.Molecules (Basel, Switzerland) · 2023Review
- Metabolomics-directed nanotechnology in viral diseases management: COVID-19 a case study.Pharmacological reports : PR · 2023Review
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundCurrently available anti-influenza drugs are often associated with limitations such as toxicity and the appearance of drug-resistant strains. Therefore, there is a pressing need for the development of novel, safe and more efficient antiviral agents. In this study, we evaluated the antiviral activity of zinc oxide nanoparticles (ZnO-NPs) and PEGylated zinc oxide nanoparticles against H1N1 influenza virus.
methodsThe nanoparticles were characterized using the inductively coupled plasma mass spectrometry, x-ray diffraction analysis, and electron microscopy. MTT assay was applied to assess the cytotoxicity of the nanoparticles, and anti-influenza activity was determined by TCID50 and quantitative Real-Time PCR assays. To study the inhibitory impact of nanoparticles on the expression of viral antigens, an indirect immunofluorescence assay was also performed.
resultsPost-exposure of influenza virus with PEGylated ZnO-NPs and bare ZnO-NPs at the highest non-toxic concentrations could be led to 2.8 and 1.2 log10 TCID50 reduction in virus titer when compared to the virus control, respectively (P < 0.0001). At the highest non-toxic concentrations, the PEGylated and unPEGylated ZnO-NPs led to inhibition rates of 94.6 and 52.2%, respectively, which were calculated based on the viral loads. There was a substantial decrease in fluorescence emission intensity in viral-infected cell treated with PEGylated ZnO-NPs compared to the positive control.
conclusionsTaken together, our study indicated that PEGylated ZnO-NPs could be a novel, effective, and promising antiviral agent against H1N1 influenza virus infection, and future studies can be designed to explore the exact antiviral mechanism of these nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.